<DOC>
	<DOCNO>NCT00398372</DOCNO>
	<brief_summary>To characterize molecular cell biology tumor cell lymphoma . The mechanism monoclonal antibody treatment rituximab epratuzumab also examine .</brief_summary>
	<brief_title>Clinical Pathologic Studies Non-Hodgkin 's Lymphoma Patients Receiving Antibody Treatment</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>NonHodgkin 's Lymphoma Patients Receiving Antibody Treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>